Phosphodiesterase 7 · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Phosphodiesterase 7 shows approved-linked disease relevance led by dysuria. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13946. Start with dysuria, then reuse UniProt Q13946 as the stable protein anchor across project notes and exports.
Start with dysuria, then reuse UniProt Q13946 as the stable protein anchor across project notes and exports.
Phosphodiesterase 7 shows approved-linked disease relevance led by dysuria. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with dysuria because it currently carries approved-linked support. Linked drugs include FLAVOXATE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHigh affinity 3',5'-cyclic-AMP phosphodiesterase 7A
Review this target as Phosphodiesterase 7, mapped to UniProt Q13946. ChEMBL maps the protein component as High affinity 3',5'-cyclic-AMP phosphodiesterase 7A. Sequence length is 482 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase 7 as ChEMBL target CHEMBL2111411, mapped to UniProt Q13946. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Phosphodiesterase 7 is the right protein anchor across sources, using UniProt Q13946 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why dysuria is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Phosphodiesterase 7 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q13946 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | High affinity 3',5'-cyclic-AMP phosphodiesterase 7A |
| UniProt Accession | Q13946 |
| Component Type | Protein |
| Sequence Length | 482 aa |
High affinity 3',5'-cyclic-AMP phosphodiesterase 7A
Review this target as Phosphodiesterase 7, mapped to UniProt Q13946. ChEMBL maps the protein component as High affinity 3',5'-cyclic-AMP phosphodiesterase 7A. Sequence length is 482 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Phosphodiesterase 7 shows approved-linked disease relevance led by dysuria. 3 more disease programs remain visible in the same review block.
Start review with dysuria because it currently carries approved-linked support. Linked drugs include FLAVOXATE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5180503 | 8.77 | IC50 | 1.7 | Preclinical |
| CHEMBL3403346 | 8.48 | IC50 | 3.3 | Preclinical |
| CHEMBL5625053 | 8.26 | IC50 | 5.5 | Preclinical |
| CHEMBL5630856 | 8.21 | IC50 | 6.1 | Preclinical |
| CHEMBL183465 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL182703 | 7.8 | IC50 | 16.0 | Preclinical |
| CHEMBL5196667 | 7.77 | IC50 | 17.0 | Preclinical |
| CHEMBL5624926 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL3646900 | 7.43 | IC50 | 37.0 | Preclinical |
| CHEMBL3646893 | 7.41 | IC50 | 39.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 19 | 46 | 6.1 |
| cell-based format | 5 | 4 | 5.5 |
| assay format | 3 | 5 | 7.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |
| protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |